Short Summary
The Commercial IPR Suit No. 481 of 2022, filed by Unilever Plc. against Anurag Tiwari and others, was settled by both the Plaintiffs and Defendants. The court accepted the Consent Minutes of Order, permitted amendments to the cause title, and disposed of the suit.
Detailed Summary
In the world of intellectual property, courtroom battles often grab the headlines. But sometimes, the most powerful resolution happens not before a judge, but across a negotiation table. The dispute between Unilever Plc. and Anurag Tiwari is a striking reminder that even the fiercest IP fights can end not with a bang, but with a handshake.
Unilever Plc., one of the world's most recognizable consumer goods companies, filed Commercial IPR Suit No. 481 of 2022 against Anurag Tiwari and two others. The suit was an intellectual property matter, signaling that Unilever believed its valuable brand assets or proprietary rights were being infringed or threatened. The defendants, including Anurag Tiwari, were drawn into a legal contest with a corporate heavyweight. What began as a formal commercial IP lawsuit set the stage for a confrontation over rights that companies like Unilever fiercely protect.
While the specific legal arguments and counter-arguments are not detailed in the public record of this case, the very filing of a Commercial IPR Suit by a multinational corporation like Unilever suggests serious allegations of intellectual property infringement or misuse. The defendants, faced with the legal and financial might of a global brand, had to weigh their options carefully. Rather than allowing the dispute to drag through years of litigation, both sides recognized the value of reaching a mutual understanding. The legal friction that typically defines such cases gave way to a pragmatic decision: settle.
On 7 June 2023, the court accepted the Consent Minutes of Order submitted by both the Plaintiffs and Defendants. The court permitted amendments to the cause title of the suit, reflecting the parties' agreement on the terms of resolution. With the settlement recorded and the amendments approved, the court formally disposed of the suit. No lengthy judgment, no precedent-setting ruling—just a clean, consensual end to a commercial IP dispute. The outcome was clear: the matter was settled, and the suit was decreed based on mutual consent.
For founders, startup leaders, and IP professionals, this case carries a powerful lesson: litigation is not always the only path, and sometimes the smartest move is to settle. Pursuing a drawn-out IP battle can drain resources, time, and energy—luxuries that startups and even established businesses cannot always afford. When both parties are willing to negotiate, a well-structured settlement can protect your interests, preserve relationships where possible, and free you to focus on what truly matters: building your business. Always weigh the cost of conflict against the value of resolution.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Bombay High Court. Understanding the court's reasoning in Unilever Plc. vs Anurag Tiwari is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Steer Engineering Private LimitedvsUvw Extruder
Steer Engineering Private Limited appealed against a commercial court order that dismissed its application for temporary injunction. The dispute centered on the alleged infringement of Patent No. 318271, titled 'Stress Concentration Free Spline Profile', which protects components used in Twin Screw Extruders. The High Court allowed the appeal and granted an interim injunction restraining the respondents from infringing the patent during the pendency of the suit.
Merck Sharp & Dohme Corp.vsAchemic Pharmaceuticals (India) Pvt. Ltd.
The commercial suit for patent infringement regarding the drug Sitagliptin was settled between Merck Sharp & Dohme Corp. (Plaintiffs) and Achemic Pharmaceuticals (India) Pvt. Ltd. (Defendant No. 1). The court accepted the settlement, decreeing the suit in favour of the plaintiffs against Defendant No. 1.
Macgregor, AlexandervsAssistant Controller Of Patents And Designs & Anr.
The appellant challenged the Assistant Controller's order dated November 19, 2020, which rejected Patent Application No. 3036/DELNP/2012 for 'Derivatives of Di(phenylpropanoid) Glycerol'. The court first condoned a delay of 479 days in re-filing the appeal and subsequently issued directions to list the matter before the Joint Registrar.
Interdigital Technology CorporationvsGuangdong Oppo Mobile
The plaintiffs claim infringement of five of their Standard Essential Patents (SEPs) by the defendants' mobile devices. They seek a permanent injunction against the manufacture and sale of these devices, along with damages.
Bdr Pharmaceuticals International Pvt LtdvsKudos Pharmaceuticals Limited & Anr
This order addresses an interim injunction application filed by Kudos Pharmaceuticals Limited (Plaintiff) against Bdr Pharmaceuticals International Pvt Ltd (Defendant). The court noted that the suit patent IN'720 was nearing its expiration date. The parties debated whether to proceed with the hearing given the imminent expiry and broader legal questions regarding patent coverage versus disclosure.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.